10-Q · May 12, 2026
In the Q1 2026 10-Q filing, Lumexa Imaging reported revenues of $267.73 million, representing a 3.8% increase year-over-year. However, the company posted a net loss per share (EPS) of -$0.20, which fell significantly…
Earnings analysis · 10-Q
LMRI earnings analysis
Filed August 13, 2026 · Our reading of the company's report
The latest report
Lumexa Imaging generated $264.162 million of revenue, 4.4% above the prior quarter and approximately 0.4% above consensus, but GAAP diluted EPS of $0.03 missed the $0.12 estimate. Management reiterated full-year revenue…
Read full summary
Lumexa Imaging generated $264.162 million of revenue, 4.4% above the prior quarter and approximately 0.4% above consensus, but GAAP diluted EPS of $0.03 missed the $0.12 estimate. Management reiterated full-year revenue and Adjusted EPS guidance and narrowed the Adjusted EBITDA range around an unchanged $238 million midpoint. The quarter also highlighted substantial execution and reporting risks: five material weaknesses remained unremediated as of June 30, 2026, while a 1% increase in adjusted SOFR would add approximately $8.2 million to annual interest expense.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $0.03
What stood out
-
Revenue grew sequentially and beat estimates
Revenue was $264.162 million, up 4.4% from $253 million in 2026 Q1 and approximately 0.4% above the $263.138 million consensus estimate.
-
Returned to GAAP profitability
GAAP diluted EPS was $0.03 versus $0.02 in 2026 Q1, indicating a return to profitability, but it was $0.09 below the $0.12 consensus estimate.
-
Full-year outlook was reiterated
Management reiterated full-year revenue guidance of $1.045 billion-$1.097 billion and Adjusted EPS guidance of $0.71-$0.77.
-
EBITDA range narrowed around same midpoint
Adjusted EBITDA guidance was narrowed to $235 million-$241 million from $234 million-$242 million, while the midpoint remained $238 million.
-
New finance platform implemented
The company implemented a new general ledger and consolidation platform during the quarter ended June 30, 2026, as part of its remediation plan.
What to watch
-
Five material weaknesses remain open
Management concluded disclosure controls were not effective as of June 30, 2026. Five material weaknesses remained unremediated, including deficiencies in the control environment, risk assessment, revenue accounting, segregation of duties, and IT general controls.
-
Variable-rate debt creates earnings sensitivity
A hypothetical 1% increase in adjusted SOFR under the Refinancing Term Loan would increase annual interest expense by approximately $8.2 million and reduce income before taxes by the same amount.
-
Financial reporting misstatement risk
The company states that its control weaknesses could result in a misstatement of substantially all account balances or disclosures, and prior weaknesses resulted in a restatement of previously issued financial statements and other audit adjustments that were immaterial.
Management's outlook
The filing excerpt does not provide new quantitative guidance. The August 12, 2026 earnings update reiterated full-year revenue guidance of $1.045 billion-$1.097 billion and Adjusted EPS guidance of $0.71-$0.77; Adjusted EBITDA guidance was narrowed to $235 million-$241 million, with the $238 million midpoint unchanged.
Earlier filings 2
10-K · March 30, 2026
Lumexa Imaging positions itself as a scaled national IDTF platform focused on advanced imaging (MRI/CT) with a 188-center footprint across 13 states and a referral network of ~102,000 physicians. Management highlights…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.